Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing

[1]  A. Janssens,et al.  A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users , 2014, Genetics in Medicine.

[2]  Shaoguang Feng,et al.  Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing , 2015, Journal of Thrombosis and Thrombolysis.

[3]  Richard Platt,et al.  Launching PCORnet, a national patient-centered clinical research network , 2014, Journal of the American Medical Informatics Association : JAMIA.

[4]  Michael J. Barry,et al.  Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. , 2014, JAMA.

[5]  J. Travis Gossey,et al.  Association of Patient Recall, Satisfaction, and Adherence to Content of an Electronic Health Record (EHR)–Generated After Visit Summary: A Randomized Clinical Trial , 2014, The Journal of the American Board of Family Medicine.

[6]  Erica A. Bowton,et al.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.

[7]  Xiang Ma,et al.  Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. , 2013, International journal of cardiology.

[8]  Joshua P Cohen,et al.  Clinical and economic challenges facing pharmacogenomics , 2012, The Pharmacogenomics Journal.

[9]  Mack T Ruffin,et al.  Family history assessment: impact on disease risk perceptions. , 2012, American journal of preventive medicine.

[10]  R. Chaisson,et al.  The ethics of testing a test: randomized trials of the health impact of diagnostic tests for infectious diseases. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Melissa A. Basford,et al.  Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping , 2012, Clinical pharmacology and therapeutics.

[12]  R. Frances.  Electronic Medical Records to Increase the Clinical Treatment of Tobacco Dependence: A Systematic Review , 2012 .

[13]  R. Altman,et al.  Pharmacogenomics: “Noninferiority” Is Sufficient for Initial Implementation , 2011, Clinical pharmacology and therapeutics.

[14]  Mathieu Beaulieu,et al.  Systematic review of pharmacoeconomic studies of pharmacogenomic tests. , 2010, Pharmacogenomics.

[15]  Wylie Burke,et al.  The rules remain the same for genomic medicine: The case against “reverse genetic exceptionalism” , 2010, Genetics in Medicine.

[16]  M. Washington,et al.  Clinical practice patterns and cost‐effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients , 2010, Cancer.

[17]  E. Elkin,et al.  Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients , 2010, Cancer.

[18]  L. Garrison,et al.  Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals , 2009, Journal of managed care pharmacy : JMCP.

[19]  M. Khoury,et al.  The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? , 2007, Genetics in Medicine.